The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Comparison of the Uptakes of Tc-99m MIBI and Tc-99m Tetrofosmin in A549, an MRP-expressing Cancer Cell, In Vitro and In Vivo

MRP발현 인체 비소세포 폐암 A549에서 Tc-99m MIBI와 Tc-99m Tetrofosmin섭취의 비교

  • Yoo, Jeong-Ah (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Jeong, Shin-Young (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Seo, Myung-Rang (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Bae, Jin-Ho (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Lee, Kyu-Bo (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Choi, Sang-Woon (Bioorganic Science Division, Korea Institute of Chemical Technology) ;
  • Lee, Byung-Ho (Bioorganic Science Division, Korea Institute of Chemical Technology) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University School of Medicine)
  • 유정아 (경북대학교 의과대학 핵의학교실) ;
  • 정신영 (경북대학교 의과대학 핵의학교실) ;
  • 서명랑 (경북대학교 의과대학 핵의학교실) ;
  • 배진호 (경북대학교 의과대학 핵의학교실) ;
  • 안병철 (경북대학교 의과대학 핵의학교실) ;
  • 이규보 (경북대학교 의과대학 핵의학교실) ;
  • 최상운 (한국화학연구소) ;
  • 이병호 (한국화학연구소) ;
  • 이재태 (경북대학교 의과대학 핵의학교실)
  • Published : 2003.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Uptakes of Tc-99m MIBI (MIBI) and Tc-99m tetrofosmin (tetrofosmin) in human non-small cell lung cancer A549, multidrug-resistance associated protein (MRP) expressing cell, were investigated in vitro and in vivo. Materials and Methods: Western blot analysis and immunohistochemistry were used for detection of MRP in A549 cells with anti-MRPr1 antibody. Cellular uptakes of two tracers were evaluated at $100{\mu}M$ of verapamil (Vrp), $50{\mu}M$ of cyclosporin A (CsA) and $25{\mu}M$ of butoxysulfoximide (BSO) after incubation with MIBI and tetrofosmin for 30 and 50 min at $37^{\circ}C$, using single cell suspensions at $1{\times}10^6cells/ml$. Radioactivities in supernatants and pellets were measured with gamma well counter. A549 cells were inoculated in each flanks of 24 nude mice. Group 1 (Gr1) and Gr3 mice were treated with only MIBI or tetrofosmin, and Gr2 and Gr4 mice were treated with 70mg/kg of CsA i.p. for 1 hour before injection of 370KBq of MIBI or tetrofosmin. Mice were sacrificed at 10, 60 and 240 min. Radioactivities of organs and tumors were expressed as percentage injected dose per gram of tissue (%ID/gm). Results: Western blot analysis of the A549 cells detected expression of MRPr1 (190 kDa) and immunohistochemical staining of tumor tissue for MRPr1 revealed brownish staining in cell membrane but not P-gp. Upon incubating A549 cells for 60 min with MIBI and tetrofosmin, cellular uptake of MIBI was higher than that of tetrofosmin. Coincubation with modulators resulted in an increase in cellular uptakes of MIBI and tetrofosmin. Percentage increase of MIBI was higher than that of tetrofosmin with Vrp by 623% and 427%, CsA by 753% and 629% and BSO by 219% and 140%, respectively. There was no significant difference in tumoral uptakes of MIBI and tetrofosmin between Gr1 and Gr3. Percentage increases in MIBI (114% at 10 min, 257% at 60 min, 396% at 240 min) and tetrofosmin uptake (110% at 10 min, 205% at 60 min, 410% at 240 min) were progressively higher by the time up to 240 min with CsA. Conclusion: These results indicate that MIBI and tetrofosmin are suitable tracers for imaging MRP-mediated drug resistance in A549 tumors. MIBI may be a better tracer than tetrofosmin for evaluating MRP reversal effect of modulators.

목적: 인체 비소세포 폐암 A549세포에서 MRP발현을 조사하고, A549세포와 종양에서 Tc-99m MIBI와 tetrofosmin의 섭취정도를 비교하여 MRP추적자로서의 성능을 알아보고자 하였다. 재료 및 방법: A549세포의 MRP발현은 MRPr1항체에 대한 western blot analysis와 면역조직화학 검사로 확인하였다. 세포내 섭취는 $37^{\circ}C$에서 $100{\mu}M$의 verapamil (Vrp), $50{\mu}M$의 cyclosporin A (CsA)와 $25{\mu}M$의 butoxysulfoximide (BSO)가 전 처리된 $1{\times}10^6$개/ml 농도의 단일세포 부유 상태에서MIBI와 tetrofosmin을 30분과 60분 동안 반응시킨 후 상층액과 침전물로 분리하여 각각의 방사능을 감마계수기로 측정하였다. 체내실험은 누드마우스에 A549세포를 이종이식하여 4군으로 나누었다. Gr1과 Gr3은 MIBI와 tetrofosmin을 각각 주사한 군들이며, Gr2와 Gr4는 CsA를 70mg/kg으로 MIBI와 tetrofosmin투여 1시간 전에 처리한 군들이다. MIBI와 tetrofosmin은 각각 370KBq용량으로 꼬리정맥 주사하고 10분, 60분, 240분 후에 동물들을 희생시켜 종양조직내의 두 방사성의약품의 장기섭취율(%ID/gm)로 계산하여 비교하였다. 결과: MRPr1 항체(clone MRPr1)를 이용하여 western blot analysis결과 A549세포는 약 190 kDa에 해당하는 MRPr1 밴드를 나타내었으며, 면역조직화학 염색검사에 의한 종양조직에서도 MRP가 발현되었음을 관찰할 수 있었다. A549세포에서 세포내 MIBI와 tetrofosmin의 섭취는 배양시간이 지남에 따라 증가 하였으며 그 섭취정도는 MIBI가 tetrofosmin보다 높았다. MRP역전제들에 의한 MIBI와 tetrofosmin의 섭취정도를 각각의 60분 대조군과 비교하면 Vrp($100{\mu}M$) 처리에 의하여 각각 623%와 427%, CsA($50{\mu}M$)에 의해서는 각각 763%와 629%, BSO ($25{\mu}M$)에 의해서는 각각 219%와 140%로 증가하여 모든 역전제에서 MIBI의 섭취증가 정도가 tetrofosmin보다 높았다. 체내에서 Gr1과 Gr3에서 두 방사성의 약품의 섭취정도는 유사하였다. Gr2와 Gr4에서 CsA (70mg/kg)에 의한 섭취정도는 각각의 대조군에 비교하여 MIBI는 10분에 114%, 60분에 257%, 240분에 396%로 증가하였으며, tetrofosmin은 10분에 110%, 60분에 205%, 240분에 410%로 증가하였다. 결론: 본 연구의 결과로 보아 인체 비소세포 폐암 A549세포와 종양에서 MIBI와 teoofosmin은 MRP발현을 측정할 수 있는 방사성의약품으로 사료되며, MRP억제제들에 의한 MIBI와 tetrofosmin의 섭취증가 정도는 세포실험에서는 MIBI가 tetrofosmin보다 높았으나 동물실험에서는 유사하였다.

Keywords

References

  1. Bradley G, Juranka PF, Ling V. Mechanism of multidrug-resitance. Biochim Biophys Acta 1988; 948:87-128
  2. Gottesman MM, Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427 https://doi.org/10.1146/annurev.bi.62.070193.002125
  3. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistance human lung cancer cell line. Science 1992;258:1650-4 https://doi.org/10.1126/science.1360704
  4. Narasaki F, Oka M, Nakano R, Ikeda K, Fukuda M, Nakamura T, et al. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cell. Biochem Biophys Res Commun 1997;240:606-11 https://doi.org/10.1006/bbrc.1997.7703
  5. Evers R, Zaman GJR, van Deemter L, Jansen H, Calafat J, Oomen LCJM, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein (MRP) in polarized pig kidney cells. J Clin Invest 1996;97:1211-8 https://doi.org/10.1172/JCI118535
  6. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF, et al. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27:1786-92 https://doi.org/10.1007/s002590000375
  7. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci 1994;91:8822-6 https://doi.org/10.1073/pnas.91.19.8822
  8. Benderra Z, Yrussardi A, Morjani H, Villa AM, Doglia SM, Manfait M. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in huaman MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer 2000;36:428-34 https://doi.org/10.1016/S0959-8049(99)00288-9
  9. Moretti JL, Cordobes MD, Starzec A, de Beco V, Vergote J, Benazzouz F, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Med 1998;39 :1214-8
  10. Perek N, Prevot N, Koumanov F, Frere D, Sabido O, Beauchesne P, et al. Involvement of the glutathione S-congugate compounds and MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol 2000;27:299-307 https://doi.org/10.1016/S0969-8051(00)00085-8
  11. Delmon-Moigeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cationhexakis(2-methoxyisobutylisonitrile)- Technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-201
  12. Palmedo H, Schomburg A, Grunwald F, Mallmann P, Boldt I, Biersack HJ. Scintimammography with Tc-99m MIBI in patients with suspicion of primary breast cancer. Nucl Med Biol 1996;23:681-4 https://doi.org/10.1016/0969-8051(96)00084-4
  13. Tonami N. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy. J Nucl Med 1997;38:501-6
  14. Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis (alkylisonitrile) technetium- 99m complexes. J Nucl Med 1990;31:1166-7
  15. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistance P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53 :977-84
  16. Ballinger JR, Banneman J, Boxen I, Firby P, Hartman NG, Moore MJ. Tc-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistance breast tumor cells. J Nucl Med 1996;37:1578-82
  17. Mansi L, Rambaldi PF, Marino G, Pecori B, Del Vecchio E. Tc-99m tetrofosmin uptake in breast tumors. J Nucl Med 1995;36S:83p
  18. Kao CH, Ho YJ, Shen YY, Lee JK. Evaluation of chemotheraphy response in patients with small cell lung cancer using technetium-99m-tetrofosmin. Anticancer Res 1999;19:2311-5
  19. Yoo JA, Chung SY, Seo MR, Kwak DS, Ahn BC, Lee KB, et al. Comparison of the uptakes of $^99m$Tc-sestamibi and $^99m$Tc-tetrofosmin in cancer cell lines expressing multidrug resistance. Korean J Nucl Med 2003;37:178-89
  20. Otsuka N, Tamada T, Mimura H, Sone T, Morita K, Tomomitsu T, et al. Comparative study on the tumor accumulation of $^99m$Tc-tetrofosmin and $^99m$Tc-MIBI in rabbits bearing VX-2cancer. Kaku Igaku 1997;34:939-43
  21. Bernard BF, Krenning EP, Breeman WA, Ensing G, Benjamins H, Bakker WH, et al. $^99m$Tc-MIBI, $^99m$Tc-Tetrofosmin and 99mTc-Q12 in vitro and in vivo. Nucl Med Biol 1998;25:233-40 https://doi.org/10.1016/S0969-8051(97)00201-1
  22. Horne T, Pappo I, Cohen-Pour M, Baumer M, Orda R. $^99m$Tc-tetrofosmin scintimammography for detecting breast cancer: a comparative study with $^99m$Tc- MIBI. Nucl Med Commun 2001;22:807-11
  23. Dole LA, Ross DD. Multidrug resistance mediated by breast cancer resistance protein BCRP(ABCG2). Oncogene 2003;20:7340-58
  24. Kuo TH, Liu FY, Chuang CY, Wu HS, Wang JJ, Kao A. To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression. Nucl Med Biol 2003;30:627-32 https://doi.org/10.1016/S0969-8051(03)00058-1
  25. Rodrigues M, Chehne F, Kalinowska W, Zielinki C, Sinzinger H. Comparative $^99m$Tc-MIBI, $^99m$Tctetrofosmin and 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines. Eur J Nucl Med 2000;27:1839-43 https://doi.org/10.1007/s002590000369
  26. Lorke DE, Kruger M, Buchert R, Bohuslavizki KH, Clausen M, Schumacher U. In vitro and in vivo tracer characterizations of an established multidrugresistant human colon cancer cell line. J Nucl Med 2001;42:646-54
  27. Cordobes MD, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian JC, Prevost G, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286-9
  28. Rodrigues M, Chehne F, Kalinowska W, Berghammer P, Zielinki C, Sinzinger H. Uptake of $^99m$Tc-MIBI and $^99m$Tc-tetrofosmin into malignant versus nonmalignat breast cell lines. J Nucl Med 2000;41:1495-9
  29. Cho IH, Lee J, Suh JS, Lee BH, Choi SW, Sohn SK, et al. Effects of new multidrug-resistance reversing agent, KR-30035, on tumoral uptake of Tc-99m MIBI in vivo and in vitro. J Korean Cancer Assoc 1999;31:773-83
  30. Kim JK, Lee J, Lee BH, Choi SW, Yoo SE, Lee SW, et al. Reversal of multidrug resistance with KR-30035: evaluated with biodistribution of Tc-99m MIBI in nude mice bearing human tumor xenografts. Korean J Nucl Med 2001;35:168-84
  31. Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Uptake of Tc-99m MIBI related to tumour size and type. Anticancer Res 1997;17:1693-4
  32. Papantoniou V, Christodoulidou J, Papadaki E, Valotassiou V, Souvatzoglou M, Louvrou A, et al. Uptake and washout of $^99m$TcV-dimercaptosuccinic acid and $^99m$Tc-sestamibi in the assessment of histological type and grade in breast cancer. Nucl Med Commun 2002;23:461-7 https://doi.org/10.1097/00006231-200205000-00006